These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 20176859)

  • 41. The psychoses: cluster 3 of the proposed meta-structure for DSM-V and ICD-11.
    Carpenter WT; Bustillo JR; Thaker GK; van Os J; Krueger RF; Green MJ
    Psychol Med; 2009 Dec; 39(12):2025-42. PubMed ID: 19796428
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Subthreshold symptoms and vulnerability indicators (e.g., eye tracking dysfunction) in schizophrenia.
    Flechtner KM; Steinacher B; Mackert A
    Compr Psychiatry; 2000; 41(2 Suppl 1):86-9. PubMed ID: 10746909
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prediction of prodromal symptoms and schizophrenia-spectrum personality disorder traits by positive and negative schizotypy: A 3-year prospective study.
    Racioppi A; Sheinbaum T; Gross GM; Ballespí S; Kwapil TR; Barrantes-Vidal N
    PLoS One; 2018; 13(11):e0207150. PubMed ID: 30408119
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Elevated nailfold plexus visibility aggregates in families and is associated with a specific negative symptom pattern in schizophrenia.
    Vuchetich JP; Liska JL; Dionisio DP; Stanwyck JJ; McGuire KA; Sponheim SR
    Psychiatry Res; 2008 Jul; 160(1):30-7. PubMed ID: 18514327
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Additional support for the cognitive model of schizophrenia: evidence of elevated defeatist beliefs in schizotypy.
    Luther L; Salyers MP; Firmin RL; Marggraf MP; Davis B; Minor KS
    Compr Psychiatry; 2016 Jul; 68():40-7. PubMed ID: 27234181
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The multidimensionality of schizotypy.
    Vollema MG; van den Bosch RJ
    Schizophr Bull; 1995; 21(1):19-31. PubMed ID: 7770738
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Predisposition to alcohol and drug consumption in schizophrenia-vulnerable people].
    Fumero A; Santamaría C; Navarrete G
    Rev Neurol; 2009 Jul 1-15; 49(1):8-12. PubMed ID: 19557693
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Exploring schizophrenia spectrum psychopathology in borderline personality disorder.
    Zandersen M; Parnas J
    Eur Arch Psychiatry Clin Neurosci; 2020 Dec; 270(8):969-978. PubMed ID: 31289925
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical characteristics of schizotypal-related obsessive-compulsive disorder.
    Poyurovsky M; Faragian S; Pashinian A; Heidrach L; Fuchs C; Weizman R; Koran L
    Psychiatry Res; 2008 May; 159(1-2):254-8. PubMed ID: 18378321
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nicotine consumption and schizotypy in first-degree relatives of individuals with schizophrenia and non-psychiatric controls.
    Esterberg ML; Jones EM; Compton MT; Walker EF
    Schizophr Res; 2007 Dec; 97(1-3):6-13. PubMed ID: 17897810
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sustained attention deficit and schizotypal personality features in nonpsychotic relatives of schizophrenic patients.
    Chen WJ; Liu SK; Chang CJ; Lien YJ; Chang YH; Hwu HG
    Am J Psychiatry; 1998 Sep; 155(9):1214-20. PubMed ID: 9734545
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Familial prevalence and coaggregation of schizotypy indicators: a multitrait family study.
    Grove WM; Lebow BS; Clementz BA; Cerri A; Medus C; Iacono WG
    J Abnorm Psychol; 1991 May; 100(2):115-21. PubMed ID: 2040761
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The schizotaxic self: phenotyping the silent predisposition to schizophrenia spectrum disorders.
    Raballo A
    Med Hypotheses; 2009 Jul; 73(1):121-2. PubMed ID: 19282109
    [No Abstract]   [Full Text] [Related]  

  • 54. The assessment of schizotypal features over two points in time.
    Squires-Wheeler E; Skodol AE; Erlenmeyer-Kimling L
    Schizophr Res; 1991 Dec; 6(1):75-85. PubMed ID: 1786236
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Schizotypal personality traits in nonpsychotic relatives are associated with positive symptoms in psychotic probands.
    Mata I; Gilvarry CM; Jones PB; Lewis SW; Murray RM; Sham PC
    Schizophr Bull; 2003; 29(2):273-83. PubMed ID: 14552503
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Associations between schizotypal features and indicators of neurological and morphological abnormalities.
    Bollini AM; Compton MT; Esterberg ML; Rutland J; Chien VH; Walker EF
    Schizophr Res; 2007 May; 92(1-3):32-40. PubMed ID: 17363219
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Schizotypy and clinical symptoms, cognitive function, and quality of life in individuals with a psychotic disorder.
    Brosey E; Woodward ND
    Schizophr Res; 2015 Aug; 166(1-3):92-7. PubMed ID: 26002072
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Schizotaxia--theoretical construct or a tool for clinical research?].
    Parnowska D
    Psychiatr Pol; 2004; 38(5):783-94. PubMed ID: 15523926
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The latent structure of schizotypy: I. Premorbid indicators of a taxon of individuals at risk for schizophrenia-spectrum disorders.
    Tyrka AR; Cannon TD; Haslam N; Mednick SA; Schulsinger F; Schulsinger H; Parnas J
    J Abnorm Psychol; 1995 Feb; 104(1):173-83. PubMed ID: 7897041
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Schizotypy: looking back and moving forward.
    Kwapil TR; Barrantes-Vidal N
    Schizophr Bull; 2015 Mar; 41 Suppl 2(Suppl 2):S366-73. PubMed ID: 25548387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.